Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile

Abstract

Background and Purpose— Comorbid cancer is common in patients with acute ischemic stroke (AIS). As blood mRNA profiles can distinguish AIS mechanisms, we hypothesized that cancer-related AIS would have a distinctive gene expression profile. Methods— We evaluated 4 groups of 10 subjects prospectively enrolled at 3 centers from 2009 to 2018. This included the group of interest with active solid tumor cancer and AIS and 3 control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable). Subjects in the vascular risk factor group were matched to subjects in the cancer-stroke and stroke-only groups by age, sex, and vascular risk factors. Blood was drawn 72 to 120 hours after stroke. Total RNA was processed using 3′ mRNA sequencing. ANOVA and Fisher least significant difference contrast methods were used to estimate differential gene expression between groups. Results— In the cancer-stroke group, 50% of strokes were cryptogenic. All groups had differentially expressed genes that could distinguish among them. Comparing the cancer-stroke group to the stroke-only group and after accounting for cancer-only genes, 438 genes were differentially expressed, including upregulation of multiple genes/pathways implicated in autophagy signaling, immunity/inflammation, and gene regulation, including IL (interleukin)-1, interferon, relaxin, mammalian target of rapamycin signaling, SQSTMI1 (sequestosome-1), and CREB1 (cAMP response element binding protein-1). Conclusions— This study provides evidence for a distinctive molecular signature in blood mRNA expression profiles of patients with cancer-related AIS. Future studies should evaluate whether blood mRNA can predict detection of occult cancer in patients with AIS. Clinical Trial Registration— URL: https://clinicaltrials.gov . Unique identifier: NCT02604667.

High neutrophil/lymphocyte ratio at cancer diagnosis predicts incidence of stroke in cancer patients

“…In the present study, the median time from cancer diagnosis to ischaemic stroke was 187 days. This result was consistent with a report by Navi et al, 29 which indicated that patients newly diagnosed with cancer had increased ischaemic stroke risk (especially during the first 6 months). Together, these results suggest that physicians should pay attention to ischaemic stroke incidence in newly diagnosed cancer patients.…”

Stroke Exacerbates Cancer Progression by Upregulating LCN2 in PMN-MDSC

“…Recently, cancer-related stroke is attracting increasing attention in clinical research. Mounting epidemiology studies suggest that cancer-bearing patients may have increased cancer progression after acute ischemic stroke, which is very common in cancer patients (14). However, it remains largely unknown how acute ischemic stroke exacerbate cancer progression in the cancer-related stroke.…”

Cancer and Embolic Stroke of Undetermined Source

“…30 We demonstrated in a small multicenter prospective study that patients with cancer and stroke have a distinctive molecular signature in their peripheral blood gene expression as compared to cancer-only and stroke-only controls. 31 Pathways specific to the cancer-stroke group primarily involved inflammation, hypoxia response, transcriptional regulation, cortical circuit plasticity, and cancer formation/progression.…”